Home
Cell Based Assays
18 November - 19 November 2013
Cell Based Assays

Special Managers Rate £799, limited availability. Book online today

Following on from our hugely successful Cell-Based Assays conference in 2012 SAE Media Group will provide a global forum for senior level decision makers and those working within Cell-Based Assays to meet.
 

Highly accurate in-vitro practices are becoming absolutely vital as is looking at cost-effective assay development. Cell based assays now play an important role into the research pipeline, making a large percentage of total research time and is set to show considerable growth over the coming years.

There are currently 15 FDA approved kinase inhibitor drugs, but there currently remains a huge uncapped potential with these drugs as over 90% of the kinome is unknown. Novel assays have identified kinase targets, improved the function of kinase inhibitors and led to an acceleration in drug discovery with new inhibitor classes.

Toxicology is generally difficult to predict, even in animal models. This has paved the way for high content screening assays using stem cell derived cardiomyocytes and hepatocytes can facilitate the determination as complex responses from specific drugs. See at cell based assays 2013 how HCA can be utilised in your pre-clinical toxicology procedures to give highly accurate tox data.

Over 13 big pharma speakers will demonstrate to you everything we need to know in CBA development including innovative case studies, including a unique 4 stage 'Big Pharma Spotlight' on Ion Channel targeting development.


 

FEATURED SPEAKERS

Anthony Davies

Anthony Davies

Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin
Fengrong Zuo

Fengrong Zuo

Principal Scientist, Group Leader Bioassays/Serology, MedImmune
Mark Mao Xiang Chen

Mark Mao Xiang Chen

Biological and Cellular Targets, , GlaxoSmithKline
Martha Brown

Martha Brown

Senior Associate Director, Compound Profiling, Boehringer Ingelheim
Michiel van Diepen

Michiel van Diepen

Scientist II, Novartis
Steve Ludbrook

Steve Ludbrook

Section Head, GlaxoSmithKline
Tyrell Norris

Tyrell Norris

Team Leader - Celluar Reagents and Assay Development, AstraZeneca
Urs Luethi

Urs Luethi

Senior Lab Head Lead Discovery, Actelion

Amir Gander

Senior Knowledge Transfer Associate, UCL Medical School
Amir Gander

Anthony Davies

Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin
Anthony Davies

David Standing

Senior Scientist, GlaxoSmithKline
David Standing

Eric Tang

Associate Principle Scientist, AstraZeneca
Eric Tang

Fengrong Zuo

Principal Scientist, Group Leader Bioassays/Serology, MedImmune
Fengrong Zuo

Gareth Griffiths

Chief Scientific Officer, Imagen Biotech
Gareth  Griffiths

Mark Mao Xiang Chen

Biological and Cellular Targets, , GlaxoSmithKline
Mark Mao Xiang Chen

Martha Brown

Senior Associate Director, Compound Profiling, Boehringer Ingelheim
Martha Brown

Michiel van Diepen

Scientist II, Novartis
Michiel van Diepen

Pamela Tranter

Investigator III, Novartis
Pamela Tranter

Paul French

Head of Photonics Group, Imperial College London
Paul French

Sian Harding

Head of Myocardial Function Section, Imperial College London
Sian Harding

Steve Ludbrook

Section Head, GlaxoSmithKline
Steve Ludbrook

Timothy Grant Hammond

Senior Medical Officer , US Department of Veterans Affairs/ Duke University
Timothy Grant  Hammond

Tyrell Norris

Team Leader - Celluar Reagents and Assay Development, AstraZeneca
Tyrell Norris

Urs Luethi

Senior Lab Head Lead Discovery, Actelion
Urs Luethi

Xavier Leroy

Associate Director, Project Leader, Actelion
Xavier Leroy

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Welcome & Introductions

clock

9:10

An overview of the main application areas of 3D assay and cell culture technologies

clock

9:45

An appraisal of all of the currently technologies and their key advantages

clock

10:45

Morning Refreshments

clock

11:00

Presentation of research data from a few selected studies using 3D assay technologies

clock

12:10

Q & A and group discussion

clock

12:30

Close of Workshop

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Anthony Davies

Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin

clock

9:10

Expanding the use of primary cell systems in hit identification and compound profiling

Steve Ludbrook

Steve Ludbrook, Section Head, GlaxoSmithKline

  • Current focus on translationally-aligned drug discovery approaches
  • Potential to accelerate the uptake of primary cell screening systems
  • Primary cell systems utilised as GSK
  • Increased usage of phenotypic assays and primary screening activities for hit identification
  • clock

    9:50

    Phenotypic screening based on automated imaging to identify EMT inhibitors

    Urs Luethi

    Urs Luethi, Senior Lab Head Lead Discovery, Actelion

  • Phenotypic rather than target-based screening
  • Generating multiparametric readout based on automated imaging
  • Identification of small molecules that block the EMT (epithelial-to-mesenchyme transition)
  • Case study
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Improving the physiological relevance of SAR-driving assays with primary and stem cells

    Martha Brown

    Martha Brown, Senior Associate Director, Compound Profiling, Boehringer Ingelheim

  • Immortalized cell lines in drug discovery
  • Overview of primary and stem cells in the context of SAR-driving assays
  • Case studies
  • clock

    11:40

    Development of high-throughput recombinant assays for ENaC drug discovery

    Mark Mao Xiang Chen

    Mark Mao Xiang Chen, Biological and Cellular Targets, , GlaxoSmithKline

  • ENaC is an important drug target 
  • Robust functional expression of  3 subunits overcoming cellular toxicity
  • Planar array electrophysiology and FLIPR assays
  • HTS and compound profiling
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    Multi-platform analysis approaches for the evaluation of in 3D biological systems in vitro

    Anthony Davies

    Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin

  • Practical issues surrounding 3D cell based assays in research
  • Experimental approaches we have under taken to implement a multiplatform analysis of in vitro assays
  • Demonstrate the feasibility of performing assays in an automated screening environment
  • clock

    14:30

    Translating drug combinations from in vitro to clinic – 2D or 3D cultures ?

    Eric Tang

    Eric Tang, Associate Principle Scientist, AstraZeneca

  • Introductions to 3D culture methods
  • Successful translations from traditional 2D methods
  • AstraZeneca case study
  • clock

    15:10

    Afternoon Tea

    clock

    15:40

    Cell-based Biomarker Assay Platforms in Support of the Clinical Development of Anti-viral Vaccines and mAbs at MedImmune

    Fengrong Zuo

    Fengrong Zuo, Principal Scientist, Group Leader Bioassays/Serology, MedImmune

  • Overview of the Cell-based Assay Platforms used for Vaccine Drug Development at MedImmune
  • Development of the Fluorescence-based RSV infectivity and its microneutralization vs MSD-based IgG assays
  • Their utility in phase I clinical study as the immunogenicity biomarkers for the Live Attenuated RSV Vaccine MEDI559
  • Performing assays in an automated screening environment
  • clock

    16:20

    Using High Content screening to compare 2D Vs 3D cell responses to a panel of chemotherapeutic agents

    Gareth  Griffiths

    Gareth Griffiths , Chief Scientific Officer, Imagen Biotech

  • Current Techniques in 3D culture
  • Using 3 Assays  (the 3D hanging drop technique, 2D, and stem cell side population) to compare different breast cancer line response to drugs
  • Description of techniques to isolate glioblastoma stem cells from patients
  • Subsequent screening of these lines in 2D Vs 3D and generation of compound ‘fingerprints’ for each line
  • clock

    17:00

    Studies of yeast metabolism in the unique culture environment of microgravity

    Timothy Grant  Hammond

    Timothy Grant Hammond , Senior Medical Officer , US Department of Veterans Affairs/ Duke University

    •         Unique opportunities afforded by space flight
    •         Low shear suspension culture
    •         Reduced gravity dependent convection for volatile gas signalling
    •         The unique pathway analysis determined in space

    clock

    17:40

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Anthony Davies

    Anthony Davies, Director of the High Content Facility, Institute of Molecular Medicine, Trinity College Dublin

    clock

    9:10

    Assay development of multi-subunit ion channels for drug discovery screening using MaxCyte electroporation: GABA-a receptors

    Tyrell Norris

    Tyrell Norris, Team Leader - Celluar Reagents and Assay Development, AstraZeneca

    Assay development for multi-subunit ion channels
    Scalable transient expression using electroporation
    Comparison of multiple assay platforms
     

    clock

    9:50

    Luciferase based Complementation assay to dissect GPCR signaling pathways

    Xavier Leroy

    Xavier Leroy, Associate Director, Project Leader, Actelion

  • GPCR pathways activation
  • GRKs, Beta-arrestin 2
  • Endosome, Lysozome, internalization
  • Biased agonists
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Strategies for screening ion channel drug discovery targets

    Pamela Tranter

    Pamela Tranter, Investigator III, Novartis

  • New technologies and  applications of automated electrophysiology platforms 
  • Approaches for developing Ion channel cell based assays
  • The challenges with  profiling transient receptor potential (TRP) ion channels
  • clock

    11:40

    Exploring capabilities of IonWorks Barracuda for ion channel safety profiling in early stage drug discovery

    David Standing

    David Standing, Senior Scientist, GlaxoSmithKline

  • Increasing throughput and lowering cost
  • Detecting slow-acting compounds
  • Extending high throughput electrophysiology to Cys-loop transmitter-gated ion channels
  • Optimising assay performance
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    A new adaptation to the BacMam system

    Michiel van Diepen

    Michiel van Diepen, Scientist II, Novartis

  • Introductions to the BacMam system
  • Recent applications of the study
  • Case study
  • clock

    14:30

    FLIM HCA from Automated Multiwell Plate Assays to Live Disease Models

    Paul French

    Paul French, Head of Photonics Group, Imperial College London

  • Flourescence lifetime imaging (FLIM)
  • Reading protein interactions in automated multiwell plate readers in live disease models
  • Application of FLIM plate reader to exemplar assay of HIV-Gay protein aggregation with dose response resulting in Z'>0.5
  • clock

    15:10

    Afternoon Tea

    clock

    15:40

    Use of human pluripotent stem cell derivatives as cardiovascular disease models

    Sian Harding

    Sian Harding, Head of Myocardial Function Section, Imperial College London

  • Human embryonic and induced pluripotent stem cells
  • Advantages of high content screening
  • Unique characteristics of cardiomyocyte cultures
  • Development of cardiotoxicity and cell growth assays
  • clock

    16:20

    Supplying Donated Human Tissue for Cell Based Assays

    Amir Gander

    Amir Gander, Senior Knowledge Transfer Associate, UCL Medical School

  • Infrastructure needed to delivery human tissue samples
  • How tissue is used at UCL
  • Industrial collaborators
  • Challenges and solutions to high quality tissue provision
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Day Two


    Biological and Cellular Targets,
    GlaxoSmithKline
    Scientist II
    Novartis
    Senior Lab Head Lead Discovery
    Actelion
    Section Head
    GlaxoSmithKline
    Head of Photonics Group
    Imperial College London
    Senior Knowledge Transfer Associate
    UCL Medical School
    Associate Principle Scientist
    AstraZeneca
    Chief Scientific Officer
    Imagen Biotech
    Senior Associate Director, Compound Profiling
    Boehringer Ingelheim
    Associate Director, Project Leader
    Actelion
    Team Leader - Celluar Reagents and Assay Development
    AstraZeneca
    Investigator III
    Novartis
    Head of Myocardial Function Section
    Imperial College London
    Director of the High Content Facility, Institute of Molecular Medicine
    Trinity College Dublin
    Senior Scientist
    GlaxoSmithKline
    Principal Scientist, Group Leader Bioassays/Serology
    MedImmune
    Senior Medical Officer
    US Department of Veterans Affairs/ Duke University

    Cell-Based Assays – Sponsor Manual

    Download

    Cell-Based Assays – Delegate Prospectus

    Download

    Closer to Real 3D Cell Culture Advances

    Download

    Novel 3D Cell Culture Systems

    Download

    Short Q&A with an Expert: Dr. Timothy Hammond

    Download

    A novel, rapid and reproducible method for creating 3-D cell cultures to study complex cell behaviour.

    Download

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.